Incyte Corp (INCY)
$76.74
1.50 (1.92%)
INCY Stock Quote Delayed 15 Minutes
Previous Close
$76.74
Market Cap
16.27B
PE Ratio
-100.97
EPS
-0.76
Volume (Avg. Vol.)
1.30M
Day's Range
75.83 - 78.76
52-Week Range
72.00 - 96.79
Dividend & Yield
N/A (N/A)
INCY Stock Predictions, Articles, and Incyte Corp News
Stock Market Today: Is the Rally Ruined?; Tesla’s New Record
Stocks were hit for what feels like the first time in a long time. Here's what happened in the stock market today.
Incyte News: INCY Stock Tumbles 10% on Experimental Drug Study Failure
Incyte (INCY) news for Friday about a recent clinical trial failing to meet its endpoints has INCY stock taking a beating.
Nasdaq Today: Semis Rally, Micron Earnings, Suing FB and GOOGL?
Trump says that Facebook and Alphabet should be sued, while Micron surged on earnings. Semiconductors got a big boost in the Nasdaq today as well.
Nasdaq Today: Maintaining Altitude Amid Uncertainty
PayPal, Slack, and chip stocks like AMD and Nvidia, Micron and Nio were all big movers in the Nasdaq today. Get the scoop, now.
3 Big Stock Charts for Wednesday: Incyte, FMC and LyondellBasell
The stock charts of INCY, LYB and FMC are going to start this week's hump-day at a precipice. Here are the numbers to know.
3 Big Stock Charts for Wednesday: Cabot Oil & Gas, Incyte and Sempra Energy
The stock charts of COG, INCY and SRE are worth a closer technical look at the midpoint of the trading week.
3 Big Stock Charts for Monday: Pfizer, MGM Resorts and Incyte
The stock charts of PFE, INCY and MGM are finally making good on previously-suggested promise.
3 Big Stock Charts for Friday: Incyte, Schlumberger and Abbott Laboratories
The stock charts of INCY, ABT and SLB are set to end the week on a more definitive, trade-worthy footing than most other names.
3 Big Stock Charts for Monday: Entergy, Incyte and SL Green Realty
The stock charts of SLG, INCY and ETR are shaping up as the best trading bets as the new week kicks off.
Incyte Corporation Stock Plunges on Melanoma Drug Trial Failure
Incyte (INCY) was falling hard on Friday following news of a failed Phase 3 drug trial for its melanoma drug epacadostat.
10 Deceptively Bad Stocks to Sell Before You’re Pranked
If you’re itching to buy, avoid these stocks at all costs. Here's what makes them stocks to sell for all wise investors.
Navellier Ratings
Powered by Portfolio GraderTotal Grade
C
